EQRx Scales Disruptive Model of Important New Medicines at Lower Prices with $500M Series B Financing

Jan 11, 2021•almost 5 years ago

Amount Raised

$500 Million

Round Type

series b

Cambridge

Description

EQRx, a company committed to developing and delivering important new medicines at lower prices, today announced that it has raised $500 million in Series B financing. Since launching a year ago, EQRx has raised approximately $750 million to advance its mission of bringing new medicines to treat life-threatening and chronic diseases to patients and healthcare systems around the world at prices that are a fraction of the cost of today’s leading therapies.

Company Information

Company

Eq Rx

Location

Cambridge, Maryland, United States

About

EQRx is committed to catalyzing a market-based solution to one of society’s biggest healthcare challenges by developing important new medicines and offering them at lower prices. Through strategic partnerships with stakeholders from across the healthcare system and cutting-edge science and technology, the Company aims to provide high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. EQRx is a purpose-built disruptor at scale, remaking medicine to bend the cost curve in drug pricing. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRxInc, LinkedIn, Instagram: @eqrxinc.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

EQRx Scales Disruptive Model of Important New Medicines at Lower Prices with $500M Series B Financing

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information